Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Insmed has been awarded a grant of $2.1 million from the Muscular Dystrophy Association. The grant is expected to cover a substantial portion of the external costs associated with Insmed's 24-week Phase III enabling trial in patients with myotonic muscular dystrophy.
Subscribe to our email newsletter
Insmed has decided to initiate the Phase III enabling trial based on promising results from an ongoing open-label, dose-escalation trial of Iplex in myotonic muscular dystrophy (MMD). To date, up to 70% of patients have reported improvements in one or more of several symptoms commonly associated with MMD.
Geoffrey Allan, Insmed’s president and CEO, said: “We are delighted to have a well-respected organization such as the Muscular Dystrophy Association (MDA) take an active role in the development of Iplex for this important indication. We believe third party commitments such as this clearly demonstrate the significance of our results to date and the validity of this approach to treat patients with this severely debilitating disease.”